Prolx Pharmaceuticals Corp.
Patent Owner
Stats
- 4 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- May 12, 2011 most recent publication
Details
- 4 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 84 Total Citation Count
- Oct 20, 1994 Earliest Filing
- 12 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
7858657 Wortmannin analogs and methods of using same in combination with chemotherapeutic agentsSep 23, 08Dec 28, 10[C07D]
7446124 Wortmannin analogs and methods of using same in combination with chemotherapeutic agentsJul 11, 05Nov 04, 08[A61K]
5602278 N-oxides and derivatives of chlorambucil for treating hypoxic tumor cellsOct 20, 94Feb 11, 97[C07F, C07C]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2011/0110,941 Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic AgentsAbandonedNov 08, 10May 12, 11[A61K, A61P]
2010/0105,072 Methods of identifying respondents to hypoxia inducible factor 1-alpha inhibitorsAbandonedOct 30, 09Apr 29, 10[G01N]
7629128 Methods of identifying respondents to hypoxia inducible factor 1-α inhibitorsExpiredApr 17, 06Dec 08, 09[G01N, C07K]
7399785 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factorExpiredAug 30, 04Jul 15, 08[A61K]
2006/0104,902 Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapyAbandonedAug 17, 05May 18, 06[A61K]
2005/0049,309 Regulation of HIF protein levels via deubiquitination pathwayAbandonedJul 14, 04Mar 03, 05[A61K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.